A compound of the formula: ##STR1## wherein R is a bridged alicyclic group selected from the group consisting of norbornyl, norbornenyl, bicyclo[2,2,2]-heptyl and adamantyl optionally substituted by at least one substituent selected from the group consisting of lower alkyl, carboxy, lower alkoxycarbonyl, alkylidenedioxy, N,N-di(lower)alkylcarbamoyl, amino, loweralkoxycarbonylamino and halogen. The present compound is useful in the therapeutic treatment of cancer in human beings and animals.

A new and industrially useful method of producing 1(or 1,3-bis)-(tetrahydro-2-furyl)-5-fluorouracil or a mixture thereof by reacting 5-fluorouracil with 2,3-dihydrofuran at elevated temperature in a closed vessel. Depending upon reaction conditions, each of the above 5-fluorouracil derivatives or a mixture of them is produced. 1,3-Bis-(tetrahydro-2-furyl)-5-fluorouracil thus formed can be converted to 1-(tetrahydro-2-furyl)-5-fluorouracil by solvolysis under non-acidic conditions.

Temperature stable 5-fluorouracil compositions are disclosed. A solution of 5-fluorouracil and a base forms the composition. The pH of the composition is about 9.1 to about 9.3. The composition is less prone to precipitate at temperatures below 60.degree. F.

1-Carbamoyl-5-fluorouracil derivatives represented by the formula ##STR1## wherein R represents alkyl containing 3-8 carbon atoms are effective oral anti-tumor agents with low toxicity.

A novel 5-fluorouracil derivative of the formula: ##STR1## wherein R.sup.1 is a fluorine-containing C.sub.1 -C.sub.10 organic group which optionally contains sulfur, oxygen and/or nitrogen. The novel 5-fluorouracil derivative is useful as a carcinostatic substance, which has a high carcinostatic activity but which is less toxicity against digestive tract and causes less autonomic imbalance than other known 5-fluorouracil derivatives.

A pharmaceutical composition in unit dosage form adapted for topical administration to a human or non-human animal in need thereof comprising a pharmacologically effective amount of a prodrug of 5-fluorouracil having the formula: ##STR1## wherein R.sub.3 is bonded to C=O by a carbon-to-carbon bond and is a group such that the prodrug (1) has an enhanced delivery across topical membranes and (2) hydrolyzes after delivery to 5-fluorouracil.

An anti-cancer composition which comprises at least one 5-fluorouracil derivative, and a uracil derivative.

A pressure-sensitive adhesive tape is provided wherein 5-fluorouracil is incorporated in a compatible, preferably self-tackified polyurethane pressure-sensitive adhesive. The tape is useful for topical treatment of abnormal skin growths. The adhesive serves as a biologically and chemically inert carrier for the 5-fluorouracil.

The reaction of certain fluorinated pyrimidine derivatives with hydrogen donor compounds to produce 6-substituted 5-fluoropyrimidines is disclosed. The products so produced are useful in germicidal and antineoplastic applications, and can be converted into 5-fluorouracil, which has known utility in cancer chemotherapy.

An anti-cancer composition comprising a 5-fluorouracil (including derivatives thereof) and uracil (or salt thereof), is disclosed, wherein the composition contains less than 0.1 mole of the 5-fluorouracil per mole of the uracil.